Trial Profile
A Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia (MTP-131) in Patients With Heart Failure Due to Reduced Left Ventricular Ejection Fraction
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2015
Price :
$35
*
At a glance
- Drugs Elamipretide (Primary)
- Indications Heart failure
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Stealth BioTherapeutics
- 14 Oct 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, according to ClinicalTrials.gov record.
- 24 Mar 2015 New trial record